Daclizumab: A potential asthma therapy?

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 4, Issue 3, 2010, Pages 214-221

  Antoniu, Sabina A ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Asthma; Cd25; Daclizumab; Subunit il 2 receptor

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA INTERFERON; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; DEPSIPEPTIDE; EOSINOPHIL CATIONIC PROTEIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; PREDNISONE; PSEUDOMONAS EXOTOXIN; STAT PROTEIN; TACROLIMUS; THYMOCYTE ANTIBODY; TRIAMCINOLONE ACETONIDE;

ACUTE GRAFT REJECTION; ACUTE GRAFT VERSUS HOST DISEASE; ADD ON THERAPY; AIRWAY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; ASTHMA; BLOOD TOXICITY; BRONCHIOLITIS OBLITERANS; CARDIAC GRAFT REJECTION; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CUTANEOUS T CELL LYMPHOMA; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; EOSINOPHIL COUNT; EYE DISEASE; EYE INFLAMMATION; FORCED EXPIRATORY VOLUME; GRAFT FAILURE; GRAFT SURVIVAL; HAIRY CELL LEUKEMIA; HODGKIN DISEASE; HUMAN; IMMUNOGENICITY; INFECTION; INFLAMMATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG FUNCTION; LUNG GRAFT REJECTION; LUNG LAVAGE; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTIPLE SCLEROSIS; NONHUMAN; NOSE CONGESTION; ORGAN TRANSPLANTATION; PEAK EXPIRATORY FLOW; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; RECOMBINANT DNA TECHNOLOGY; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SEPSIS; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN INFECTION; T CELL LEUKEMIA; T LYMPHOCYTE ACTIVATION; TOXICITY TESTING; UNSPECIFIED SIDE EFFECT; UVEITIS;

EID: 78649378650     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221310793564254     Document Type: Article

References (58)

1. Brandhuber BJ, Boone T, Kenney WC, McKay DB. Three- dimensional structure of interleukin-2. Science 1987; 238(4834): 1707-9.
2. Church AC. Clinical advances in therapies targeting the interleukin-2 receptor. QJM 2003; 96(2): 91-102.
3. Leonard WJ, Depper JM, Crabtree GR, Rudikoff S, Pumphrey J, Robb RJ, et al. Molecular cloning and expression of cDNAs for the human interleukin-2 receptor. Nature 1984; 311(5987): 626-31.
4. Noguchi M, Nakamura Y, Russell SM, Ziegler SF, Tsang M, Cao X, et al. Interleukin-2 receptor gamma chain: A functional component of the interleukin-7 receptor. Science 1993; 262(5141): 1877-80.
5. Waldmann TA. The interleukin-2 receptor. J Biol Chem 1999; 266(5): 2681-4.
6. Zenapax. European Public Assessment Report 2010.
7. FOOD AND DRUG A. Zenapax
8. Schuurman, J., Havenith, C.E.G., Parren, P., Van de WinkeL, J.G.J., Williams, D.L., Petersen, J., Baadsgaard, O. Human monoclonal antibodies against CD25. US7438907 (2008).
9. Queen C, Schneider WP, Selick HE, payne PW, Landolfi NF, Duncan JF, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989; 86(24): 10029-33.
10. Schuurman, J., Havenith, C.E.G., Parren, P., Van de WinkeL, J.G.J., Williams, D.L., Petersen, J., Baadsgaard, O. Human monoclonal antibodies against CD25. US20090081219 (2009).
11. Assignee S. LU0090411A9: Daclizumab In. Luxembourg: Protein Design Labs. Inc: USA1999.
12. European Medicines Agency. Public statement on Zenapax (daclizumab) Withdrawal of the marketing authorisation in the European Union 2009.
13. Mastrobuoni S, Ubilla M, Cordero A, Herreros J, Rabago G. Twodose daclizumab, tacrolimus, mycophenolate mofetil, and steroidfree regimen in de novo cardiac transplant recipients: Early experience. Transplant Proc 2007; 39(7): 2163-6.
14. Ailawadi G, Smith PW, Oka T, Wang H, Kozower BD, Daniel TM, et al. Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation. J Thorac Cardiovasc Surg 2008; 135(3): 594-602.
15. Foroncewicz B, Mucha K, Ryszkowska E, Ciszek M, Ziółkowski J, Porowski D, et al. Safety and efficacy of steroid-free immunosuppression with tacrolimus and daclizumab in liver transplant recipients: 6-year follow-up in a single center. Transplant Proc 2009; 41(8): 3103-6.
16. Otero A, Varo E, de Urbina JO, Martín-Vivaldi R, Cuervas-Mons V, González-Pinto I, et al. A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids. Liver Transpl 2009; 15(11): 1542-52.
17. Zanfi C, Lauro A, Cescon M, Dazzi A, Ercolani G, Grazi GL, et al. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: Rejection and infection rates in 40 recipients during the early postoperative period. Transplant Proc 2010; 42(1): 35-8.
18. Rao K, Rao A, Karlsson H, Jagani M, Veys P, Amrolia PJ. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroidrefractory graft-versus-host disease. J Pediatr Hematol Oncol 2009; 31(6): 456-61.
19. Perales MA, Ishill N, Lomazow WA, Weinstock DM, Papadopoulos EB, Dastigir H, et al. Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graftvs- host disease. Bone Marrow Transplant 2007; 40(5): 481-6.
20. Miano M, Cuzzubbo D, Terranova P, Giardino S, Lanino E, Morreale G, et al. Daclizumab as useful treatment in refractory acute GVHD: A paediatric experience. Bone Marrow Transplant 2009; 43(5): 423-7.
21. Waldmann TA, Levy R, Coller BS. Emerging therapies: Spectrum of applications of monoclonal antibody therapy. Hematol Am Soc Hematol Educ Prog 2000: 394-408.
22. Pillips KE, Herring B, Wilson LA, Rickford MS, Zhang M, Goldman CK, et al. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction. Cancer Res 2000; 60(24): 6977-84.
23. Waldmann TA, White JD, Goldman CK, Top L, Grant A, Bamford R, et al. The interleukin-2 receptor: A target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood 1999; 82(6): 1701-12.
24. Waldmann TA. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: A 25-year personal odyssey. J Clin Immunol 2007; 27(1): 1-18.
25. Waldmann TA. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene 2007; 26(25): 3699-703.
26. Chen J, Zhang M, Ju W, Waldmann TA. Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25. Blood 2009; 113(6): 1287-93.
27. Morris JC, Waldmann TA. Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis 2000; 59 (Suppl 1): i109-14.
28. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000; 18(8): 1622-36.
29. Waldmann TA, White JD, Carrasquillo JA, Reynolds JC, Paik CH, Gansow OA, et al. Radioimmunotherapy of interleukin-2R alphaexpressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood 1995; 86(11): 4063-75.
30. O'Mahony D, Morris JC, Carrasquillo JA, Le N, Paik CH, Whatley M. Phase I/II study of Yttrium-90 labeled humanised anti-tac(HAT) monoclonal antibody and calcium DTPA in CD25-expressing malignancies. J Nucl Med 2006; 47: 98.
31. Bielekova B, Becker Bl. Monoclonal antibodies in MS: mechanisms of action. Neurology 74 (Suppl 1): S31-40.
32. Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, McCartin J, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 2004; 101(23): 8705-8.
33. Martin, R., McFarland, H. F., Bielekova, B., Waldmann, T. Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist. WO2004002500 (2004).
34. Martin, R., McFarland, H.F, Bielekova, B., Waldmann, T. Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist. US20090175823 (2009).
35. Leung, S., Li, L., Liu, X., Lu, H., Tsui, P., Zang, J. Treatment of autoimmune and inflammatory disease. US20100040616 (2010).
36. Rose JW, Watt HE, White AT, Carlson NG. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 2004; 56(6): 864-7.
37. Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007; 69(8): 785-9.
38. Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): A phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010; 9(4): 381-90.
39. Sen HN, Levy-Clarke G, Faia LJ, Li Z, Yeh S, Barron KS, et al. High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am J Ophthalmol 2009; 148(5): 696-703.
40. Nussenblatt RB, Thompson DJ, Li Z, Peterson JS, Robinson RR, Shames RS, et al. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: Long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun 2003; 21(3): 283-93.
41. Bhat P, Castaneda-Cervantes RA, Doctor PP, Foster CS. Intravenous daclizumab for recalcitrant ocular inflammatory disease. Graefes Arch Clin Exp Ophthalmol 2009; 247(5): 687-92.
42. Yeh S, Wroblewski K, Buggage R, Li Z, Kurup SK, Sen HN, et al. High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis. J Autoimmun 2008 31(2): 91-7.
43. Antoniu SA. Cytokine antagonists for the treatment of asthma: Progress to date. BioDrugs 2009; 23(4): 241-51.
44. Davis BE, Illamperuma C, Gauvreau GM, Watson RM, O'Byrne PM, Deschesnes F, et al. Single-dose desloratadine and montelukast and allergen-induced late airway responses. Eur Respir J 2009; 33(6): 1302-8.
45. Davis BE, Todd DC, Cockcroft DW. Effect of combined montelukast and desloratadine on the early asthmatic response to inhaled allergen. J Allergy Clin Immunol 2005; 116(4): 768-72.
46. Corrigan CJ, Hartnell A, Kay AB. T lymphocyte activation in acute severe asthma. Lancet 1988; 1(8595): 1129-32.
47. Walker C, Kaegi MK, Braun P, Blaser K. Activated T cells and eosinophilia in bronchoalveolar lavages from subjects with asthma correlated with disease severity. J Allergy Clin Immunol 1991; 88(6): 935-42.
48. Park CS, Lee SM, Uh ST, Kim HT, Chung YT, Kim YH, et al. Soluble interleukin-2 receptor and cellular profiles in bronchoalveolar lavage fluid from patients with bronchial asthma. J Allergy Clin Immunol 1993; 91(2): 623-33.
49. Park CS, Lee SM, Chung SW, Uh S, Kim HT, Kim YH. Interleukin-2 and soluble interleukin-2 receptor in bronchoalveolar lavage fluid from patients with bronchial asthma. Chest 1994; 106(2): 400-6.
50. Ben-Shoshan M. Omalizumab: Not only for asthma. Recent Pat Inflamm Allergy Drug Discov 2008; 2(3): 191-201.
51. Arima M, Yukawa T, Terashi Y, Makino S. Effect of inhaled cyclosporin A on the allergen-induced late asthmatic response and increased in airway hyperresponsiveness in a guinea pig model of asthma. Arerugi 1994; 43(11): 1316-25.
52. Fukuda T, Akutsu I, Motojima S, Makino S. Inhibition of antigeninduced late asthmatic response and bronchial hyperresponsiveness by cyclosporin and FK 506. Int Arch Allergy Appl Immunol 1991; 94(1-4): 259-61.
53. Alexander AG, Barnes NC, Kay AB. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 1992; 339(8789): 324-8.
54. Lock SH, Kay AB, Barnes NC. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med 1996; 153(2): 509-14.
55. Alexander AG, Barnes NC, Kay AB, Corrigan CJ. Clinical response to cyclosporin in chronic severe asthma is associated with reduction in serum soluble interleukin-2 receptor concentrations. Eur Respir J 1995; 8(4): 574-8.
56. Nizankowska E, Soja J, Pinis G, Bochenek G, Sladek K, Domagala B, et al. Treatment of steroid-dependent bronchial asthma with cyclosporin. Eur Respir J 1995; 8(7): 1091-9.
57. Fukuda T, Asakawa J, Motojima S, Makino S. Cyclosporine A reduces T lymphocyte activity and improves airway hyperresponsiveness in corticosteroid-dependent chronic severe asthma. Ann Allergy Asthma Immunol 1995; 75(1): 65-72.
58. Busse WW, Israel E, Nelson HS, Baker JW, Charous BL, Young DY, et al. Daclizumab Asthma Study Group. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: A randomized, controlled trial. Am J Respir Crit Care Med 2008; 178(10): 1002-18.